<DOC>
	<DOCNO>NCT00281866</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase II trial study well erlotinib work treat patient recurrent and/or metastatic head neck cancer .</brief_summary>
	<brief_title>Erlotinib Treating Patients With Metastatic and/or Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine relationship response rate number CA repeat intron 1 epidermal growth factor receptor ( EGFR ) patient metastatic and/or locally recurrent squamous cell carcinoma head neck ( SCCHN ) treat EGFR inhibitor erlotinib hydrochloride . Secondary - Determine relationship number CA repeat intron 1 EGFR gene time disease progression survival patient treated drug . - Determine cutaneous toxicity erlotinib hydrochloride patient different number CA repeat intron 1 EGFR gene . - Compare degree p27 upregulation EGFR phosphorylation skin biopsy sample patient different number CA repeat intron 1 EGFR gene treat drug . - Determine relationship erlotinib hydrochloride exposure ( utilizing total unbound erlotinib hydrochloride concentration ) outcome , toxicity , pharmacodynamic effect ( upregulation p27 ) patient different number CA repeat . OUTLINE : This multicenter study . Patients stratify accord genotype intron 1 epidermal growth factor receptor ( 16/16 vs 16/20 20/20 ) . Patients receive oral erlotinib hydrochloride daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 37 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck Metastatic and/or locally recurrent disease No undifferentiated nonkeratinizing carcinoma , include lymphoepitheliomas location , well tumor parotid gland WHO Type I squamous cell carcinoma nasopharynx allow Incurable surgery radiotherapy Measurable disease , define ≥ 1 target lesion ≥ 20 mm OR ≥ 10 mm spiral CT scan If site measurable disease previously irradiate area , patient must document progressive disease tomography biopsyproven residual carcinoma No symptomatic brain metastasis stable , adequately control fixeddose oral steroid , potentially lifethreatening , require radiotherapy within last 14 day PATIENT CHARACTERISTICS : ECOG performance status 02 Predicted life expectancy ≥ 12 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST and/or ALT ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must practice effective contraceptive measure No prior malignancy within past 3 year except adequately treat basal cell squamous cell skin cancer situ cervical cancer No active uncontrolled infection serious illnesses medical condition No history psychiatric condition might impair patient 's ability understand comply requirement study provide inform consent PRIOR CONCURRENT THERAPY : See Disease Characteristics No two prior chemotherapy regimen locally recurrent and/or metastatic disease Prior induction chemotherapy chemoradiotherapy curative intent local disease allow provided patient receive two prior chemotherapy regimens recurrent disease Prior therapy must complete minimum 14 day prior study AND patient recover No prior moleculardirected therapy , tyrosine kinase inhibitor and/or monoclonal antibody At least 14 day must elapse end radiotherapy study registration recover At least 14 day since prior surgery AND wound healing occur At least 7 day since prior herbal extract tincture CYP3A inhibitory activity , include follow : Hydrastis canadensis ( goldenseal ) Uncaria tomentosa ( cat 's claw ) Echinacea angustifolia root Trifolium pratense ( wild cherry ) Matricaria chamomilla ( chamomile ) Glycyrrhiza glabra ( licorice ) Dillapiol Naringenin No concurrent anticancer therapy investigational agent No concurrent administration follow : Phenytoin Carbamazepine Rifampicin Barbiturates Hypericum perforatum ( St. John 's wort ) CYP3A inhibitor ( e.g. , itraconazole )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
</DOC>